Alfred M Pediatric Registry for Mechanically Assisted Circulatory Support
|
|
- Adrian Flowers
- 6 years ago
- Views:
Transcription
1 1 #HHSN C Alfred M Pedimacs Pediatric Registry for Mechanically Assisted Circulatory Support Quarterly Statistical Report rd Quarter Implant and event dates: September 19, 2012 to September 30, /18/2017 Prepared by: The Data and Clinical Coordinating Center University of Alabama at Birmingham For questions or comments contact: James K. Kirklin, MD Betsy Blume, MD Craig Collum, MPH Nick Timkovich Kathryn Hollifield, RN Maceo Cleggett
2 2 #HHSN C Pedimacs Quarterly Report Coverage: September 19, 2012 to September 30, 2017 The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) is a North American registry established in 2005 for patients who are receiving mechanical circulatory support device therapy to treat advanced heart failure. Intermacs was established as a joint effort of the National Heart, Lung and Blood Institute (NHLBI), the Centers for Medicare and Medicaid Services (CMS), the Food and Drug Administration (FDA), clinicians, scientists and industry representatives in conjunction with Dr. James K. Kirklin and the University of Alabama at Birmingham. Pedimacs is the pediatric portion of Intermacs which was launched on 9/19/2012. While Intermacs has always included durable devices implanted in pediatric patients, Pedimacs has been developed to focus on capturing data elements unique to pediatric patients. Pedimacs evaluates special issues in the pediatric population receiving Mechanical Circulatory Support Device (MCSD) therapy, differences in devices available, and the particular pediatric population for whom this therapy may be most effective. Elizabeth Blume, M.D. from the Children's Hospital Boston, is the Pedimacs Chair. This quarterly report includes clinical information from 507 pediatric patients receiving prospective implants between September 19, 2012 and September 30, Table of Contents Exhibit 1: Pedimacs Participating Hospitals Exhibit 2: Pedimacs Enrollment Counts Exhibit 3: Pedimacs Patients - Temporary vs Durable Devices Exhibit 4: Pedimacs Patients Receiving Durable Devices - Demographics Exhibit 5: Pedimacs Patients Receiving Durable Devices - Device Type Exhibit 6: Pedimacs Patients Receiving Durable Devices - Patient Profile Exhibit 7: Pedimacs Patients Receiving Durable Devices - Device Strategy Exhibit 8: Pedimacs Patients Receiving Durable Devices - Patient Profile by Device Strategy Exhibit 9: Pedimacs Patients Receiving Durable Devices - Patient Status by Pre-Implant Device Strategy Exhibit 10: Pedimacs Patients Receiving Durable Devices - Primary Cause of Death Exhibit 11: Kaplan-Meier Survival for Durable Devices Exhibit 12: Kaplan-Meier Survival for Continuous Durable Devices Exhibit 13: Kaplan-Meier Survival for Pulsatile Durable Devices Exhibit 14: Competing Outcomes for Durable Devices Exhibit 15: Competing Outcomes for Continuous Durable Devices Exhibit 16: Competing Outcomes for Pulsatile Durable Devices Glossary
3 3 Exhibit 1: Pedimacs Participating Hospitals As of February 16, 2017 there are 70 hospitals enrolled in Pedimacs of whom 46 contributed data used in this report. SITE HOSPITAL NAME CITY STATE MNAN Abbott Northwestern Hospital Minneapolis MN ILCM Ann & Robert H. Lurie Children s Hospital of Chica Chicago IL ARCH Arkansas Children's Hospital Little Rock AR AZUA Banner Univ. Medical Center (Univ. of Arizona) Tucson AZ TNBM Baptist Memorial Hospital - Memphis Memphis TN MOBH Barnes-Jewish Hospital St. Louis MO NCCM Carolinas Medical Center Charlotte NC CACS Cedars Sinai Medical Center Los Angeles CA GAEH Children's Healthcare of Atlanta Atlanta GA MACH Children's Hospital Boston Boston MA WICH Children's Hospital of Wisconsin Milwaukee WI TXCM Children's Medical Center Dallas TX MOCM Children's Mercy Hospital Kansas City MO DCCH Children's National Medical Center Washington DC OHCM Cincinnati Children's Hospital Medical Center cincinnati OH OHCC Cleveland Clinic Cleveland OH NYCP Columbia Presbyterian - Children's Hospital of New New York NY NYCP Columbia University Medical Center-NY Presbyterian New York NY NCDU Duke University Medical Center Durham NC PAUP Hospital of the University of Pennsylvania Philadelphi PA TXMH Houston Methodist Hospital Houston TX WASH Inland Northwest Thoracic Organ Transplant Program Spokane WA FLJM Jackson Memorial Health System/University of Miami Miami FL CAKPX Kaiser Permanente Santa Clara Medical Center Santa Clara CA CAUH Keck Hospital of USC Los Angeles CA INLH Lutheran Hospital of Indiana Fort Wayne IN AZMC Mayo Clinic Hospital Phoenix AZ FLSL Mayo Clinic Jacksonville Jacksonvill FL MNSM Mayo Clinic Rochester MN Rochester MN TXHD Medical City Dallas Hospital Dallas TX SCMU Medical University of South Carolina Medical Cente Charleston SC INIM Methodist Hospital Indianapoli IN TXHS Methodist Specialty and Transplant Hospital San Antonio TX MOLH Mid America Heart Institute of Saint Luke's Hospit Kansas City MO NYMA Montefiore Medical Center Bronx NY
4 4 Exhibit 1: Pedimacs Participating Hospitals SITE HOSPITAL NAME CITY STATE NYMS Mount Sinai Medical New York NY OHCH Nationwide Children's Hospital Columbus OH DEAI Nemours/A.I. dupont Hospital for Children Wilmington DE NCBG North Carolina Baptist Hospital Winston Sal NC LAOF Ochsner Medical Center New Orleans LA ORUO Oregon Health & Science University Portland OR PAPPX Penn Presbyterian Medical Center Philadelphi PA PAHE Penn State Milton S. Hershey Medical Center Hershey PA CACH Rady Children's Hospital, San Diego San Diego CA WACH Seattle Children's Hospital Seattle WA VANG Sentara Norfolk General Hospital Norfolk VA FLUF Shands at the University of Florida Gainesville FL MOCH St. Louis Children's Hospital St. Louis MO INSV St. Vincent Hospital and Health Care Center Indianapoli IN CASU Stanford University Medical Center Stanford CA CASG Sutter Memorial Hospital Sacramento CA TXTC Texas Children's Hospital Houston TX PACP The Children's Hospital of Philadelphia Philadelphi PA COCH The Childrens Hospital Denver CO MDJH The Johns Hopkins Hospital Baltimore MD CAUC UCLA Medical Center Los Angeles CA ALUA University of Alabama at Birmingham Hospital Birmingham AL CASD University of California, San Diego Medical Center San Diego CA ILUC University of Chicago Hospitals Chicago IL IAIV University of Iowa Hospitals and Clinics Iowa City IA KYUK University of Kentucky Chandler Medical Center Lexington KY MDUM University of Maryland Medical Center Baltimore MD MIUM University of Michigan Health Systems Ann Arbor MI MNUM University of Minnesota Medical Center-Fairview Minneapolis MN NECH University of Nebraska Children's Hospital Omaha NE NCMH University of North Carolina Hospitals Chapel Hill NC PAPT University of Pittsburgh Medical Center Pittsbugh PA UTMC University of Utah Hospital Salt Lake C UT VAUV University of Virginia Health System Charlottesv VA DCWH Washington Hospital Center Washington DC
5 5 Exhibit 2: Pedimacs Enrollment Counts As of September 30, 2017 there were 70 hospitals participating in Pedimacs of whom 46 contributed prospective data used in this report.
6 6 Exhibit 3: Pedimacs Patients - Temporary vs Durable Devices Exhibits that are displayed after this exhibit are based on each patients first durable device.
7 7 Exhibit 4: Pedimacs Patients Receiving Durable Devices - Demographics The following tables present demographic characteristics for patients at the time of their first durable device implant (September 19, 2012 to September 30, 2017). Age Group AGE Pulsatile Continuous All n % n % n % <1 yr yr yr yr yr TOTAL Gender GENDER Pulsatile Continuous All n % n % n % Female Male TOTAL Race RACE Pulsatile Continuous All n % n % n % White African American Other TOTAL
8 8 Exhibit 5: Pedimacs Patients Receiving Durable Devices - Device Type First Durable Device Type GENDER Pulsatile Continuous All n % n % n % LVAD BiVAD TAH TOTAL
9 9 Exhibit 6: Pedimacs Patients Receiving Durable Devices - Patient Profile Patient profile status provides a general clinical description of the patients at the time of implantation. PRE-IMPLANT PATIENT PROFILE Pulsatile Continuous All n % n % n % 1. Critical Cardiogenic Shock Progressive Decline Stable but Inotrope Dependent Resting Symptoms or Less Sick TOTAL Critical cardiogenic shock describes a patient who is 'crashing and burning', in which a patient has life-threatening hypotension and rapidily escalating inotropic pressor support. 2. Progressive decline describes a patient who has been demonstrated 'dependent' on inotropic support, but nonetheless shows signs of continuing deterioration. 3. Stable but inotrope dependent describes a patient who is clinically stable on mild-moderate doses of intravenous inotropes. 4. Resting symptoms describe a patient who is at home on oral therapy, but frequently has symptoms of congestion at rest or with ADL. 5. Exertion Intolerant describes a patient who is comfortable at rest, but unable to engage in any activity, living predominantly within the house or household. 6. Exertion Limited also describes a patient who is comfortable at rest without evidence of fluid overload, but who is able to do some mild activity. 7. Advanced NYHA Class 3 describes a patient who is clinically stable with a reasonable level of comfortable activity, despite history of previous decompensation that is not recent.
10 10 Exhibit 7: Pedimacs Patients Receiving Durable Devices - Device Strategy Device strategy is determined in conjunction with the heart failure cardiologist and surgeon at the time of the implant. PRE-IMPLANT DEVICE STRATEGY Pulsatile Continuous All n % n % n % Bridge to Recovery Bridge to Transplant (patient currently listed for transplant) Possible Bridge to Transplant - Likely to be eligible Possible Bridge to Transplant - Moderate likelihood of becoming eligible Possible Bridge to Transplant - Unlikely to become eligible Destination Therapy (patient definitely not eligible for transplant) Rescue Therapy TOTAL Bridge to Transplant (BTT) Listed - patient already listed for transplant or listed within 24 hours before device implantation. 2. Bridge to Transplant (BTT) Likely - patient in whom the transplant evaluation has not been completed, but no contra-indications are anticipated, or in whom a current contra-indication is anticipated to resolve rapidly. 3. Bridge to Transplant (BTT) Moderate - patient in whom the transplant evaluation has not been completed, but with some potential concerns that might prevent eligibility. 4. Bridge to Transplant (BTT) Unlikely - patient in whom major concerns that might prevent eligibility have already been identified. 5. Destination Therapy - the patient is definitely not eligible for transplant. 6. Bridge to Recovery (BTR) - use of a durable device to allow recovery from chronic cardiac failure (at least 3 months in duration). 7. Rescue Therapy - use of a durable device to support resolution from an acute event without major previous cardiac dysfunction. 8. Other.
11 11 Exhibit 8: Pedimacs Patients Receiving Durable Devices - Patient Profile by Device Strategy The following tables present patient profile status by the device strategy for different flow types. Type=Pulsatile PATIENT PROFILE STATUS. Bridge to Recovery Pre-Implant Device Strategy Bridge to Transplant - Listed Bridge to Candidacy Destination Therapy Rescue Therapy TOTAL n % n % n % n % n % n % n % % % % % 1. Critical Cardiogenic Shock % % % % % % 2. Progressive Decline % % % % 3. Stable but Inotrope Dependent % % % 4-7. Resting Symptoms or Less Sick % % % TOTAL % % % % % % % Type=Continuous Pre-Implant Device Strategy PATIENT PROFILE STATUS Bridge to Recovery Bridge to Transplant - Listed Bridge to Candidacy Destination Therapy TOTAL n % n % n % n % n % % % % 1. Critical Cardiogenic Shock % % % % % 2. Progressive Decline % % % % % 3. Stable but Inotrope Dependent % % % 4-7. Resting Symptoms or Less Sick % % % % TOTAL % % % % %
12 12 Exhibit 9: Pedimacs Patients Receiving Durable Devices - Patient Status by Pre-Implant Device Strategy The following tables present patient status as of September 30, 2017 by the device strategy for different time periods. Patient status is defined as the first of the following events: Alive (device in place): patients that were alive on a device at the end of this follow-up period. Transplant: patients that have received a transplant during this follow-up period. Recovery: patients that were explanted due to recovery at or before the end of this follow-up period. Dead: patients who died during this follow-up period. Type=Pulsatile Patient Status (September 30, 2017) PRE-IMPLANT DEVICE STRATEGY 1. Alive on a device 2. Transplanted 3. Death 4. Explant due to recovery TOTAL N N N N N Bridge to Recovery Bridge to Transplant (patient currently listed for transplant) Possible Bridge to Transplant - Likely to be eligible Possible Bridge to Transplant - Moderate likelihood of becoming eligible Possible Bridge to Transplant - Unlikely to become eligible Destination Therapy (patient definitely not eligible for transplant) Rescue Therapy TOTAL Type=Continuous Patient Status (September 30, 2017) PRE-IMPLANT DEVICE STRATEGY 1. Alive on a device 2. Transplanted 3. Death 4. Explant due to recovery TOTAL N N N N N Bridge to Recovery Bridge to Transplant (patient currently listed for transplant) Possible Bridge to Transplant - Likely to be eligible Possible Bridge to Transplant - Moderate likelihood of becoming eligible Possible Bridge to Transplant - Unlikely to become eligible Destination Therapy (patient definitely not eligible for transplant) TOTAL
13 13 Exhibit 10: Pedimacs Patients Receiving Durable Devices - Primary Cause of Death PRIMARY CAUSE OF DEATH Pulsatile Continuous All n % n % n % Circulatory: Other, Specify Device Malfunction Major Infection Respiratory: Respiratory Failure Circulatory: Sudden Unexplained Death Circulatory: Major Bleeding Circulatory: CHF Circulatory: End Stage Cardiomyopathy Circulatory: Ischemic Cardiomyopathy Nervous System: Neurological Dysfunction Multisystem Organ Failure (MSOF) Withdrawal of Support, specify Other, specify TOTAL Note: 0 patients have a missing primary cause of death.
14 14 Exhibit 11: Kaplan-Meier Survival for Durable Devices Percent Survival [% (70% CI)] Months after Device Implant Pedimacs Durable Dev % (91.5%-94.2%) % (81.5%-85.8%) % (74.9%-80.5%) % (71.5%-78.2%) % (47.5%-62.7%) % (37.4%-56.9%) % (37.4%-56.9%)
15 15 Exhibit 12: Kaplan-Meier Survival for Continuous Durable Devices Percent Survival [% (70% CI)] Months after Device Implant Durable CF % (96.9%-98.9%) % (87.7%-92.3%) % (82.8%-88.8%) % (79.6%-87.1%) % (54.7%-71.8%) % (43.0%-65.2%) % (43.0%-65.2%)
16 16 Exhibit 13: Kaplan-Meier Survival for Pulsatile Durable Devices Percent Survival [% (70% CI)] Months after Device Implant Durable PF % (82.1%-88.0%) % (69.5%-77.6%) % (59.6%-70.0%) % (55.4%-67.3%)
17 17 Exhibit 14: Competing Outcomes for Durable Devices Number of Patients at Risk Month
18 18 Exhibit 15: Competing Outcomes for Continuous Durable Devices Number of Patients at Risk Month
19 19 Exhibit 16: Competing Outcomes for Pulsatile Durable Devices Number of Patients at Risk Month
20 20 Exhibit 17: Follow-up Compliance Site compliance is determined by the percentage of all follow-up forms that are due during this reporting period that have been completed. This calculation has been updated to include ALL follow-up forms expected for ALL patients and ALL devices. Only sites that have at least 5 follow-up forms expected are included in this figure. Intermacs has defined required compliance as 90%.
21 21 Glossary BiVAD: BiVentricular Assist Device BMI: Body Mass Index BP: Blood Pressure BSA: Body Surface Area BTC: Bridge to Candidacy BTT: Bridge to Transplant BUN: Blood Urea Nitrogen CF: Continuous CMS: Centers for Medicare and Medicaid COPD: Chronic Obstructive Pulmonary Disease CNS: Central Nervous System CRP: C - Reactive Protein CVA: Cerebrovascular Accident DCC: Data Coordinating Center DT: Destination Therapy ECMO: Extracorporeal-membrane Oxygenation EQ-5D: Euro Quality of Life FDA: Federal Drug Administration HF: Heart Failure IABP: Intra-Aortic Balloon Pump IgG: Immunoglobulin G INR: International Normalized Ratio Intermacs: Interagency Registry for Mechanically Assisted Circulatory Support LVAD: Left Ventricular Assist Device LVEF: Left Ventricular Ejection Fraction LVEDD: Left Ventricular End Diastolic Dysfunction LVSF: Left Ventricular Shortening Fraction MCSD: Mechanically Circulatory Support Device NHLBI: National Heart Lung and Blood Institute NIH: National Institute of Health NT pro brain natriuretic peptide: N-Terminal pro brain Natriuretic peptide NYHA: New York Heart Association OR: Operating Room Pedimacs: Pediatric Registry for Mechanically Assisted Circulatory Support PF: Pulsatile Regurg: Regurgitation RVAD: Right Ventricular Assist Device RVEF: Right Ventricular Ejection Fraction SAE: Serious Adverse Event SGOT-AST: Serum Glutamic Oxaloacetic Transaminase SGPT-ALT: Serum Glutamic Pyruvic Transaminase TAH: Total Artificial Heart TIA: Transient Ischemic Attack VAD: Ventricular Assist Device VAS: Visual Analog Scale
Pedimacs. Quarterly Statistical Report. Pediatric Registry for Mechanically Assisted Circulatory Support
1 #HHSN268201100025C Alfred M 14 69 112.5 Pedimacs Pediatric Registry for Mechanically Assisted Circulatory Support Quarterly Statistical Report 2017 2nd Quarter Implant and event dates: September 19,
More informationQuarterly Statistical Report
01/04/2008 Page 1 of 26 INTERMACS Interagency Registry for Mechanically Assisted Circulatory Support Quarterly Statistical Report Implant dates: March 1, 2006 November 30, 2007 January 4, 2008 Prepared
More informationINTERMACS Interagency Registry for Mechanically Assisted Circulatory Support
INTERMACS Interagency Registry for Mechanically Assisted Circulatory Support Quarterly Statistical Report Centers for Medicare & Medicaid Services 2013 1st Quarter Implant and event dates: June 23, 2006
More informationINTERMACS Interagency Registry for Mechanically Assisted Circulatory Support
INTERMACS Interagency Registry for Mechanically Assisted Circulatory Support Quarterly Statistical Report 2012 4th Quarter Implant and event dates: June 23, 2006 to December 31, 2012 Prepared by: The Data
More informationINTERMACS Interagency Registry for Mechanically Assisted Circulatory Support
INTERMACS Interagency Registry for Mechanically Assisted Circulatory Support Quarterly Statistical Report 2013 1st Quarter Implant and event dates: June 23, 2006 to March 31, 2013 Prepared by: The Data
More informationIntermacs. Quarterly Statistical Report. Interagency Registry for Mechanically Assisted Circulatory Support
1 Alfred M 14 69 112.5 Intermacs Interagency Registry for Mechanically Assisted Circulatory Support Quarterly Statistical Report 2016 Q2 Implant and event dates: June 23, 2006 to June 30, 2016 09/26/2016
More informationInteragency Registry for Mechanically Assisted Circulatory Support. Quarterly Statistical Report
1 #HHSN268201100025C Intermacs Interagency Registry for Mechanically Assisted Circulatory Support Quarterly Statistical Report 2017 Q3 Implant and event dates: June 23, 2006 to September 30, 2017 12/18/2017
More informationNo Other Company Discloses Higher Transplant Survival Rate. Infusions For Emerging Treatments. Date of Use. Recipient Age (yrs)
Units Used In Transplants/Infusions No Other Company Discloses Higher Transplant Survival Rate Family Banking Provides Exclusive Access To Emerging Treatments With Your Own Cells 175 85% Type 1 Diabetes
More informationPredicting Major Outcomes after MCSD Implant. Risk Factors for Death, Transplant, and Recovery. James Kirklin, MD David Naftel, PhD
Predicting Major Outcomes after MCSD Implant Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD 1 I have no financial disclosures (I am the Principle Investigator for
More information2010 International Nanny Association Salary and Benefits Survey Information in this report is based on the year About Survey Respondents
2010 International Nanny Association Salary and Benefits Survey Information in this report is based on the year 2009 Five hundred and eighty-five (585) in-home child care providers responded to this survey.
More informationFifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients
http://www.jhltonline.org SPECIAL FEATURE Fifth INTERMACS annual report: Risk factor analysis from more than 6, mechanical circulatory support patients James K. Kirklin, MD, a David C. Naftel, PhD, a Robert
More informationVolunteering in Oklahoma City, OK
6/17/2010 Oklahoma City Profile - Volunteering in information on volunteering and civic engagement Volunteering in Oklahoma City, OK Statistics for this area were collected within the Oklahoma City Metropolitan
More informationSeventh INTERMACS annual report: 15,000 patients and counting
http://www.jhltonline.org INTERMACS ANNUAL REPORT Seventh INTERMACS annual report: 15,000 patients and counting James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationDouble- and Single-Lung Transplantation: An Analysis of Twenty Years of OPTN/UNOS Registry Data
1 CHAPTER 1 Double- and Single-Lung Transplantation: An Analysis of Twenty Years of OPT/UOS Registry Data Junchao Cai Terasaki Foundation Laboratory, Los Angeles, CA, USA The number of lung transplants
More informationHIV/AIDS and other Sexually Transmitted Diseases (STDs) in the Southern Region of the United States: Epidemiological Overview
HIV/AIDS and other Sexually Transmitted Diseases (STDs) in the Southern Region of the United States: Epidemiological Overview Prepared by The Henry J. Kaiser Family Foundation for Southern States Summit
More informationINTERMACS Interagency Registry for Mechanically Assisted Circulatory Support
Alfred M 14 69 112.5 INTERMACS Interagency Registry for Mechanically Assisted Circulatory Support Quarterly Statistical Report 2013 3rd Quarter Implant and event dates: June 23, 2006 to September 30, 2013
More information2018 National Oncologists Workforce Study OCTOBER 2018
2018 National Oncologists Workforce Study OCTOBER 2018 Introduction Providers have long cautioned that the U.S. healthcare system is facing imminent physician shortages across many different specialties.
More informationRegional Differences in Utilization and Outcomes of Left Ventricular Assist Devices: Insights from the INTERMACS Registry
Regional Differences in Utilization and Outcomes of Left Ventricular Assist Devices: Insights from the INTERMACS Registry Selim Krim, MD 1 ; Rey Vivo, MD 2 ; Patrick Campbell, MD 1 ; Jerry Estep, MD 3
More informationChapter Two Incidence & prevalence
Chapter Two Incidence & prevalence Science is the observation of things possible, whether present or past. Prescience is the knowledge of things which may come to pass, though but slowly. LEONARDO da Vinci
More informationConcomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis
Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis April 11, 2014 Jason O. Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil
More informationINTERMACS Interagency Registry for Mechanically Assisted Circulatory Support
Alfred M 14 69 112.5 INTERMACS Interagency Registry for Mechanically Assisted Circulatory Support Quarterly Statistical Report 2013 4th Quarter Implant and event dates: June 23, 2006 to December 31, 2013
More informationHow do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS
How do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS Rey P. Vivo, MD 1 ; Selim R. Krim, MD 2 ; Jerry D. Estep, MD 3 ; Wissam
More informationIntermacs Interagency Registry for Mechanically Assisted Circulatory Support
Alfred M 14 69 112.5 Intermacs Interagency Registry for Mechanically Assisted Circulatory Support Quarterly Statistical Report 2014 1st Quarter Implant and event dates: June 23, 2006 to March 31, 2014
More informationNational & International Lectures
2005-2008 National & International Lectures 6/24/05 ECFS Crete, Greece Mucoid Psuedomonas aeruginosa Infection, Antibiotic Resistance, and Lung Disease Progression in Children with Cystic Fibrosis 9/30/05
More informationWhat has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD
What has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD Disclosure: I am Director of the Data Coordinating Center for the INTERMACS project and receive support through
More information"The Most Challenging Places to Live with Asthma"
"The Most Challenging Places to Live with Asthma" The Asthma Capitals is an annual research project of the Asthma and Allergy Foundation of America (AAFA) to identify "the most challenging places to live
More informationSixth INTERMACS annual report: A 10,000-patient database
http://www.jhltonline.org INTERMACS ANNUAL FEATURE Sixth INTERMACS annu report: A 10,000-patient database James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationPredicting Outcomes in LVAD Recipients
Predicting Outcomes in LVAD Recipients Sean P. Pinney, MD Director, Advanced Heart Failure & Cardiac Transplantation Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai New York,
More informationVentricular Assist Devices for Permanent Therapy: Current Status and Future
Ventricular Assist Devices for Permanent Therapy: Current Status and Future Prospects Francis D. Pagani MD PhD Professor of Cardiac Surgery University of Michigan April 28 th, 2012 Disclosures NHLBI and
More informationSASI Analysis of Funds Distributed in the United States By the Centers for Disease Control and Prevention (CDC) Pursuant to PS
SASI Analysis of Funds Distributed in the United States By the Centers for Disease Control and Prevention (CDC) Pursuant to PS17-1704 1 April 13, 2017 INTRODUCTION In the Summer of 2016, the Centers for
More informationAAll s well that ends well; still the fine s the crown; Whate er the course, the end is the renown. WILLIAM SHAKESPEARE, All s Well That Ends Well
AAll s well that ends well; still the fine s the crown; Whate er the course, the end is the renown. WILLIAM SHAKESPEARE, All s Well That Ends Well mthree TrEATMENT MODALITIES 7 ž 21 ATLAS OF ESRD IN THE
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More information% $0 $ % $1,954,710 $177, % $0 $ % $0 $ % $118,444 $59, Mississippi
ATTACHMENT A Palmetto GBA Hospice Cap Overpayments by State As of May 3, 26 Item State Total % completed Total O/P Average O/P # Code State Providers Completed With O/P with O/P Amount Amount Alabama 4
More informationZhiwei Zhang, Ph.D. National Opinion Research Center
Drug and Alcohol Use and Related Matters Among Arrestees 2003 Zhiwei Zhang, Ph.D. National Opinion Research Center Acknowledgement This publication was developed for the National Institute of Justice (NIJ),
More informationBridge to Heart Transplantation
Bridge to Heart Transplantation Ulf Kjellman MD, PhD Senior Consultant Surgeon Heart Centre KFSH&RC 1 Disclosure Appointed for Proctorship by Thoratec/St.Jude/Abbott 2 To run a full overall covering transplant
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationThe Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System
The Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System A prospective, multicenter, non randomized study to evaluate the safety and efficacy of the Medtronic AVE Driver Coronary Stent
More informationSPRINT SCHEDULE NO. 11 1st Revised Page Originating Locations for Business Communications Services
1st Revised Page 1 9. SERVICE AREAS AND RATE STEP TABLES 1. Service Locations 1. Originating Locations for Business Communications Services Sprint Clarity, Sprint Premiere, Real Solutions, Business Sense
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationDo you have myelofibrosis?
Do you have myelofibrosis? Learn more about a clinical study. What Is a Clinical Study? A clinical study is a way to evaluate a drug in people with a certain illness. Some clinical studies (or clinical
More informationWalk. Give. To help them live. November 23
PROJECT 13 PARTNERSHIP: St. Jude Children s Research Hospital 2013 Give thanks. Walk. Toolkit Walk. Give. To help them live. November 23 Delta Sigma Theta Sorority, Inc. is proud to continue our support
More informationState Cd. PG1 Inst Name. Madigan Army Med Ctr
Specialty Inst City Inst City Specialty Anesthesiology Anesthesiology Anesthesiology Anesthesiology Anesthesiology Anesthesiology Anesthesiology/ UC San Francisco-CA Critical Care FRANCISCO CA C Walter
More informationHeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update
HeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update Mark S. Slaughter, MD University of Louisville, KY, USA HeartWare Users Meeting 29 October 2012 Barcelona, Spain HEARTWARE,
More informationVanderbilt Heart and Vascular Institute 2013 Comprehensive Advanced Heart Failure Summit
Vanderbilt Heart and Vascular Institute 2013 Comprehensive Advanced Heart Failure Summit Friday, August 9, 2013 7:00 AM Registration/Breakfast 7:55 AM Welcome and Opening Remarks Simon Maltais, M.D., Ph.D.,
More informationExhibit 1. Change in State Health System Performance by Indicator
Exhibit 1. Change in State Health System Performance by Indicator Indicator (arranged by number of states with improvement within dimension) Access and Affordability 0 Children ages 0 18 uninsured At-risk
More informationAndrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More informationUpdate on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada
Update on Mechanical Circulatory Support AATS May 5, 2010 Toronto, ON Canada Disclosures NONE Emergency Circulatory Support ECMO Tandem Heart Impella Assessment Cardiac Function Pulmonary function Valvular
More informationU.S. Apartment Markets Outlook
Market Advisory Services U.S. Apartment Markets Outlook Recent surge in absorption lays foundation for better performance ahead 1 Year-Year Change in 20-34 Employment (000) 2000 2001 2002 2003 2004 2005
More informationThe PROACT Trial: valve choice has changed
The PROACT Trial: valve choice has changed Marc W. Gerdisch, MD On behalf of the PROACT Investigators; Chief Cardiovascular and Thoracic Surgery Co-director Franciscan Heart Valve Center Cardiac Surgery
More informationBOTCHED ABORTION REPORTS
BOTCHED ABORTION REPORTS Following is a list of apparently botched abortions at abortion clinics. Unless otherwise noted (self admission = self admission to hospital), all required transportation to a
More informationC/PG2 Specialty Desc. C/PG2 Inst Name. Emory Univ SOM-GA. Child Neurology. Massachuset ts Gen Hosp North Shore Med Ctr/Salem Hosp-MA Orange Park
Inst City e e Emory Univ SOM-GA Anesthesiology ATLANTA GA A Anesthesiology Ctr- Anesthesiology BOSTON C Anesthesiology Ctr- Anesthesiology BOSTON C Anesthesiology UC San Francisco-CA Anesthesiology SAN
More informationProgr am Code Specialty. Preliminary Institution. Emory Univ SOM-GA. Child Neurology
City State Emory Univ SOM-GA Anesthesiology ATLANTA GA A Anesthesiology Ctr- Anesthesiology BOSTON C Anesthesiology Ctr- Anesthesiology BOSTON C Anesthesiology UC San Francisco-CA Anesthesiology SAN FRANCISCO
More informationEarly Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study
Early Experience of Transcatheter Mitral Valve Replacement Results from the Paul Sorajja, MD for the Investigators Presenter Disclosure Information Within the past 12 months, I or my spouse/partner have
More informationASAIO 64 th Annual Conference Turning Ideas In To Solutions Through Innovation June 13 16, 2018 Washington, DC
Program Outline 2018 December 7, 2017 ASAIO 64 th Annual Conference Turning Ideas In To Solutions Through Innovation June 13 16, 2018 Washington, DC www.asaio.com 8:30am 4:30pm 7 th Annual Pediatric Medical
More informationSurgical Options for Advanced Heart Failure
Surgical Options for Advanced Heart Failure Benjamin Medalion, MD Director, Transplantation and Heart Failure Surgery Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Hospital Heart
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More informationRadiation Therapy Staffing and Workplace Survey 2016
Radiation Therapy Staffing and Workplace Survey 2016 2016 ASRT. All rights reserved. Reproduction in any form is forbidden without written permission from publisher. TABLE OF CONTENTS Executive Summary...
More informationHow to mend a broken heart: transplantation or LVAD?
SCDU DI CARDIOCHIRURGIA Università degli Studi di Torino Ospedale S. Giovanni Battista Direttore: Prof. Mauro Rinaldi How to mend a broken heart: transplantation or LVAD? Massimo Boffini Mauro Rinaldi
More information2003 National Immunization Survey Public-Use Data File
SECTION 1. ID, WEIGHT AND FLAG VARIABLES Section 1 Variable Name SEQNUMC Label UNIQUE CHILD IDENTIFIER Frequency of Missing/Non-missing Values All Data 30930 21310 NON-MISSING CHARACTER STRING 000011 MINIMUM
More informationECMO as a Bridge to Heart Transplant in the Era of LVAD s.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania ECMO as a Bridge to Heart Transplant in the Era of
More informationISHLT ACADEMY MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT (MCS)
ISHLT ACADEMY MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT (MCS) Saturday, April 30, 2016 1:45 PM 6:30 PM Marriott Wardman Park Hotel, Washington, DC, USA WASHINGTON BALLROOMS 1 & 2 ISHLT ACADEMY MASTER
More informationA Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD
A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD SK Singh MD MSc, DK Pujara MBBS, J Anand MD, WE Cohn MD, OH Frazier MD, HR Mallidi MD Division of Transplant & Assist
More informationA Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial
A Fully Magnetically Levitated Left Ventricular Assist Device Final Report of the MOMENTUM 3 Trial Mandeep R. Mehra, MD, Nir Uriel, MD, Joseph C. Cleveland, Jr., MD, Daniel J. Goldstein, MD, National Principal
More informationASAIO 64 th Annual Conference Turning Ideas Into Solutions Through Innovation June 13 16, 2018 Washington, DC
Program Outline 2018 December 14, 2017 ASAIO 64 th Annual Conference Turning Ideas Into Solutions Through Innovation June 13 16, 2018 Washington, DC www.asaio.com 8:30am 4:30pm 7 th Annual Pediatric Medical
More informationOverview of MCS in Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation
Overview of MCS in 2017 Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation Technology Embracing Progress Technology Adoption Internet Adoption of Technology Pioneer in the
More informationCAPE FEAR VALLEY PHYSICIAN REFERRAL DIRECTORY
CAPE FEAR VALLEY PHYSICIAN REFERRAL DIRECTORY 2 0 0 6-2 0 0 7 Orthopaedics Christopher J. Barnes, MD Ohio State University College of Medicine, Columbus, OH Duke University Medical Center, Durham, NC Southern
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationIBM ServicePac Warranty Service Upgrade (WSU)
IBM Maintenance Services ServicePac for Warranty and Maintenance Options IBM ServicePac Warranty Service Upgrade (WSU) Supported Products April 26, 2011 IBM ServicePac Warranty Service Upgrade Post-warranty
More informationDr. Brian Gray 2011 Lecture Schedule
Dr. Brian Gray 2011 Lecture Schedule Jan. 4 New York, NY New York University School of Dentistry Jan.5 USA Connect Live Webinar, Case Jan. 28 Boston, MA Yankee Dental Conference Invisalign Certification-
More informationNovel Devices for End-Stage Heart Failure
Novel Devices for End-Stage Heart Failure Lynne Warner Stevenson No conflicts of interest Off-label assist devices and expanded indications will be discussed Devices for End-Stage Heart Failure New definitions
More informationUpdate on Pediatric Procedure Targeted Modules: Spinal Fusion Procedures Brian Brighton, MD, MPH Carolinas Healthcare System/Levine Childrens
Update on Pediatric Procedure Targeted Modules: Spinal Fusion Procedures Brian Brighton, MD, MPH Carolinas Healthcare System/Levine Childrens Hospital Charlotte, NC Disclosures I have no financial disclosures
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: September 30, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: September 30, 2013 ClinicalTrials.gov ID: NCT00758043 Study Identification Unique Protocol ID: VX08-950-111 Brief
More informationOverview of the States Pesticide Registration Process AAPCO Laboratory Committee
Overview of the States Pesticide Registration Process AAPCO Laboratory Committee Feb 16 th, 2011 Ana Cristina Rodriguez Manager, State Registration/Regulatory Affairs DuPont Crop Protection March 6, 2017
More informationMechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
More information*All Local Monthlies Data releases are scheduled from 9:00pm - 11:00pm for the date shown on the schedule
JUNE 2017 Local Monthlies Release Schedule Market Name Sequence *All Local Monthlies Data releases are scheduled from 9:00pm - 11:00pm for the date shown on the schedule Market Name Market Type Local Monthlies*
More informationB&T Format. New Measures. Better health care. Better choices. Better health.
1100 13th Street NW, Third Floor Washington, DC 20005 phone 202.955.3500 fax 202.955.3599 www.ncqa.org TO: Interested Organizations FROM: Patrick Dahill, Assistant Vice President, Policy DATE: February
More informationWomen s health status is one of the strongest determinants of how women use the health care system. The
Women s health status is one of the strongest determinants of how women use the health care system. The poorer their health, the more women need and benefit from high-quality, appropriate care. Overall,
More informationGlobal Outcomes in Pediatric Liver Transplantation
Global Outcomes in Pediatric Liver Transplantation Vicky Lee Ng, MD FRCPC The Hospital for Sick Children, University of Toronto Seattle Children s Hospital: Pediatric Liver Transplant Family Education
More informationVAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More information50-STATE REPORT CARD
JANUARY 2014 The State of Reproductive Health and Rights: 50-STATE REPORT CARD U.S. REPRODUCTIVE HEALTH AND RIGHTS AT A CROSSROADS The status of reproductive health and rights in the U.S. is at an historic
More informationTHE 2016 DENTAL MEETINGS AND EXHIBITS CALENDAR
HEADLINE 2016 DENTAL MEETINGS AND EXHIBITS CALENDAR The 151st Midwinter Meeting: Three Days of Dental Excellence Chicago Dental Society Chicago, Illinois February 25 27 cds.org/mwm ADA 2016 Annual Meeting
More informationTranscatheter Aortic Valve Replacement with a Repositionable Self-expanding Bioprosthesis in Patients With Severe Aortic Stenosis Suboptimal for
Transcatheter Aortic Valve Replacement with a Repositionable Self-expanding Bioprosthesis in Patients With Severe Aortic Stenosis Suboptimal for Surgery: One-Year Results from the Evolut R US Pivotal Study
More information2014 OREGON STATE FOOTBALL MEDIA GUIDE ALL-TIME SERIES RECORDS ALL-TIME SERIES RECORDS OVERTIME HISTORY. #GoBeavs
ALL-TIME SERIES RECORDS 2014 OREGON STATE FOOTBALL MEDIA GUIDE ALL-TIME SERIES RECORDS OPPONENT TOTAL H A N LAST Akron......................... 1-0 1-0 0-0 0-0 1987 Albany Athletic Club.......... 1-0 1-0
More informationEarly Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study
Early Experience of Transcatheter Mitral Valve Replacement Results from the Paul Sorajja, MD for the Investigators Presenter Disclosure Information Within the past 12 months, I or my spouse/partner have
More informationReduced Anticoagulation After Mechanical Valve Replacement: Interim Results from the PROACT Randomized FDA IDE Trial
Reduced Anticoagulation After Mechanical Valve Replacement: Interim Results from the PROACT Randomized FDA IDE Trial John D. Puskas, MD, FACS, FACC Emory University National Principal Investigator On Behalf
More informationThe National Cancer Institute Cancer Centers Program. The Cancer Centers Program of the National Cancer Institute (NCI) supports major
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s The National Cancer Institute
More informationCirrhosis and Liver Cancer Mortality in the United States : An Observational Study Supplementary Material
Cirrhosis and Liver Cancer Mortality in the United States 1999-2016: An Observational Study Supplementary Material Elliot B. Tapper MD (1,2) and Neehar D Parikh MD MS (1,2) 1. Division of Gastroenterology
More informationBridging With Percutaneous Devices: Tandem Heart and Impella
Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED HEART FAILURE, TX AND MCS SENTARA HEART HOSPITAL NORFOLK, VA PROFESSOR OF MEDICINE
More informationHow Can Electronic Health Records Help Practice Quality and Efficiency?
How Can Electronic Health Records Help Practice Quality and Efficiency? Michele C. Lim, MD Professor Of Ophthalmology Vice Chair and Medical Director UC Davis Eye Center I have no financial disclosures
More informationVocational Rehabilitation Funding for a Power Wheelchair with Power Adjustable Seat Height:
Vocational Rehabilitation Funding for a Power Wheelchair with Power Adjustable Seat Height: The Americans with Disabilities Act (ADA) was signed into law on July 26, 1990. It is a wide-ranging law intended
More informationThe indicators studied in this report are shaped by a broad range of factors, many of which are determined by
Health Care Payments and Workforce The indicators studied in this report are shaped by a broad range of factors, many of which are determined by policies made at the state level. State-level policies help
More informationDestination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT.
DT Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT. ONLY WE HAVE THIS BREADTH OF CLINICAL EVIDENCE TO SUPPORT DESTINATION THERAPY.
More informationVENTRICULAR ASSIST DEVICES AND TOTAL ARTIFICIAL HEARTS
Status Active Medical and Behavioral Health Policy Section: Surgery Policy Number: IV-86 Effective Date: 03/26/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationB&T Format. New Measures. 2 CAHPS is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ).
TO: Interested Organizations FROM: Patrick Dahill, Assistant Vice President, Policy DATE: February 4, 2018 RE: 2018 Accreditation Benchmarks and Thresholds This document reports national benchmarks and
More informationSupplementary Online Content
Supplementary Online Content Swaminathan S, Sommers BD,Thorsness R, Mehrotra R, Lee Y, Trivedi AN. Association of Medicaid expansion with 1-year mortality among patients with end-stage renal disease. JAMA.
More informationAnalysis of Pump Thrombosis in the Intermacs Database
Analysis of Pump Thrombosis in the Intermacs Database Michael Acker William Measey Professor of Surgery Chief of Division of Cardiovascular Surgery Director of Heart and Vascular Center University of Pennsylvania
More informationManagement of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist
Dr Stephen Pettit, Consultant Cardiologist Cardiogenic shock Management of Cardiogenic Shock Outline Definition, INTERMACS classification Medical management of cardiogenic shock PA catheters and haemodynamic
More information